Piramal Invests $55 million on API Expansions

(c) Piramal
(c) Piramal

Piramal Pharma Solutions (PPS) is spending $55 million across its sites in North America and Asia to expand its API manufacturing capacities and capabilities.

“With these investments, we can now support the  commercialization of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships,” said CEO  Vivek Sharma.

The Indian contract manufacturer will spend part of the investment on new multi-purpose plants, totalling more than 270,000 liters, to support its late-stage programs.

In addition, PPS will expand potency capability at its plant in Riverview, Michigan, USA, to a new occupational exposure limit of ≥10 ng/m3, and add GMP kilo laboratories and a pilot plant in Ennore, India, to increase its early development capabilities.

In Morpeth, UK, PPS will increase early development capabilities in both drug substances and drug products to better serve its European biotech customers.

Support functions such as analytical capabilities, R&D infrastructure, automation and IT systems will also be expanded at all API sites.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.